AB101, is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes for the control of hyperglycemia.
Your browser (Internet Explorer 7 or lower) is out of date. It has known security flaws and may not display all features of this and other websites. Learn how to update your browser.
Date: Monday, March 10th 2014
Time: 5:30 PM PST
Webcast Link: http://wsw.com/webcast/roth28/antb
We believe AB101 represents a highly differentiated and truly unique product opportunity in the large and rapidly growing diabetes market. More
Beyond diabetes, our proprietary microparticle manufacturing technology can be applied to a variety of drug development opportunities. More
Our PEGylated formulation has been designed to release insulin without an initial burst in a uniform manner over a period of approximately one week. More
Our management team is made up of proven industry veterans who have successfully started up and managed biotechnology organizations. More
AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. Our development strategy combines FDA-approved pharmaceutical agents with our proprietary delivery technology. Our lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes.
We believe that our development strategy increases the probability of technical success while reducing safety and efficacy concerns, approval risks, and overall development costs. We also believe that our approach will result in significantly improved and more efficacious therapies with substantial benefits to the global diabetic population.